References

Non-alcoholic fatty liver disease

10.1016/s0140-6736(20)32511-3 · 2021 · External reference

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

10.1016/j.cgh.2021.12.002 · 2022 · External reference

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

10.1002/hep.29466 · 2018 · External reference

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

10.1016/j.jhep.2019.06.021 · 2019 · External reference

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S

10.2337/dc19-1113 · 2020 · External reference

The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments

10.1038/s41575-021-00448-y · 2021 · External reference

Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies

10.3390/biomedicines11020468 · 2023 · External reference

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

10.1016/j.jhepr.2019.07.002 · 2019 · External reference

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

10.1016/s2468-1253(21)00261-2 · 2022 · External reference

Current treatment of non-alcoholic fatty liver disease

10.1111/joim.13531 · 2022 · External reference

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

10.1016/j.jhep.2022.04.003 · 2022 · External reference

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

10.1111/apt.16608 · 2021 · External reference

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

10.1056/nejmoa2028395 · 2021 · External reference

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

10.3390/nu14214673 · 2022 · External reference

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

10.1007/s13300-021-01011-3 · 2021 · External reference

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

10.2337/dc18-0165 · 2018 · External reference

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

10.1007/s10620-019-5477-1 · 2020 · External reference

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study

10.3390/biomedicines11020322 · 2023 · External reference

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

10.1111/dom.13907 · 2020 · External reference

Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study

10.1002/hep4.2005 · 2022 · External reference

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

10.1136/bmj.e7586 · 2013 · External reference

Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)

10.1111/1751-2980.12685 · 2019 · External reference

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024

2024 · External reference

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD

10.1002/hep.21496 · 2007 · External reference

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

10.1002/hep.21178 · 2006 · External reference

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man

10.1007/bf00280883 · 1985 · External reference

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

10.1053/j.gastro.2019.01.042 · 2019 · External reference

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

10.1007/s12325-020-01498-5 · 2020 · External reference

The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease

10.14309/ajg.0000000000000433 · 2019 · External reference

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

10.1002/hep.29367 · 2018 · External reference

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-/-) and LDLr(-/-) Mice by a Mechanism That Includes Inflammatory Pathways

10.1016/j.jacbts.2018.09.004 · 2018 · External reference

Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

10.1002/hep4.1562 · 2020 · External reference

The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease

10.1097/mol.0000000000000857 · 2023 · External reference

The Liver-α-Cell Axis in Health and in Disease

10.2337/dbi22-0004 · 2022 · External reference

SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

10.1016/j.metabol.2023.155657 · 2023 · External reference